A study to assess the usefulness of combination of Vitamin D, magnesium and Vitamin B12 in older COVID-19 patients

A cohort study to evaluate the effect of combination vitamin D, magnesium and vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN15324611

Enrollment

Registered

2020-06-01

Start date

2020-04-06

Completion date

Unknown

Last updated

2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations

Interventions

Therapy comprised a single daily oral dose of vitamin D3 1000 IU, magnesium 150 mg and vitamin B12 500 mcg for up to 14 days, with follow-up to Day 30 from onset of symptoms.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All consecutive COVID-19-positive patients aged 50 years and above admitted to Singapore General Hospital during the study period

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
The risk of clinical deterioration, defined as the requirement for supplemental oxygen and/or intensive care support, measured using patient records from hospital information system at day 30	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Singapore

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026